Diagnostics & Precision Testing

GRAIL announced in September 2026 that its Galleri multi-cancer early detection blood test showed strong performance in the PATHFINDER 2 study and received a favorable U.S. FDA advisory committee vote supporting its safety, benefit-risk profile and effectiveness for use alongside standard screening in adults aged 50 and older. The PATHFINDER 2 data indicated that adding Galleri increased cancers detected through screening more than six-fold with a very low false-positive rate, while the test also accurately pointed doctors to the likely cancer origin in over nine out of ten positive cases. The advisory committee's favorable vote and the PATHFINDER 2 results reinforce the core near-term catalyst around potential PMA approval and payer coverage, though GRAIL's high cash burn and lack of profitability remain the biggest risk. GRAIL's narrative projects $348.4 million revenue and $60.1 million earnings by 2029, with a $97.40 fair value implying a 32% downside to its current price, while some of the lowest estimate analysts were assuming only about US$277.6 million of revenue and a small US$49.4 million profit by 2029.

Dexcom released its 2026 "State of Type 2 Report: Global Access and Attitudes to Diabetes Technology" ahead of the 62nd Annual Meeting of the European Association for the Study of Diabetes, highlighting gaps in continuous glucose monitoring awareness and access while pointing to growing potential for combining CGM with GLP-1 therapies. The survey of more than 800 healthcare professionals and 2,500 people with Type 2 diabetes across eight countries found that 89% of HCPs believe CGM helps assess treatment adherence between appointments, yet 55% of surveyed Type 2 patients reported limited knowledge of the technology, and reimbursement and coverage challenges were cited by 90% of U.S. HCPs and 53% of HCPs in the other seven countries surveyed. Among existing users, 94% said CGM helps them manage diabetes more independently and 91% use CGM data to guide treatment decisions. The report also flagged an emerging intersection between CGM and GLP-1 therapies, with 58% of Type 2 patients taking GLP-1 medicines using CGM alongside their medication versus only 27% of Type 2 patients not using insulin, while half of HCPs expect increasing GLP-1 use to drive CGM adoption. Dexcom also partnered with Team Novo Nordisk, an all-diabetic professional cycling team principally sponsored by Novo Nordisk, to extend its visibility within the Type 1 diabetes community and create opportunities for real-world research, education and awareness.

NURA Bangkok Clinic, or Fujifilm DKH (Thailand) Co., Ltd., has announced a partnership with Sukhumvit 62 Medical Co., Ltd., or Ruamjairak Hospital, through the signing of a memorandum of understanding, or MOU, appointing Ruamjairak Hospital as the first Care Partner Network of NURA Bangkok Clinic. The collaboration is part of the development of a Continuity of Care Ecosystem, linking everything from preventive health checkups and early-stage risk screening to further diagnosis, access to specialist doctors, and appropriate, continuous and timely treatment. NURA Bangkok Clinic focuses on health checkups and preventive screening for cancer and heart disease through screening programs for cancer and non-communicable chronic diseases, or NCDs, using an Ultra Low-Dose CT Scan together with Fujifilm's AI-powered analysis system, under the concept of a complete examination within 120 minutes, from the start of the scan to seeing a doctor, with clients not required to fast or abstain from water beforehand. Under this collaboration, if screening results at NURA Bangkok Clinic reveal a risk or abnormality requiring further examination, clients can be referred to Ruamjairak Hospital to proceed with further diagnosis, consultation with specialist doctors, and appropriate treatment. Sittivech Sawetphat, General Manager of Fujifilm DKH (Thailand) Co., Ltd., said the company aims to encourage Thais to recognize the importance of preventive health checkups and early-stage screening for cancer and cardiovascular disease risk. Meanwhile, Apirak Apisanthanarak, Managing Director of Ruamjairak Hospital, said the collaboration reflects a shared goal of building a patient-centered healthcare system.

ABL Texcell Diagnostics has raised its full-year 2026 revenue guidance to between €13.5 million and €14.0 million, up from the €12.265 million target it announced on 1 June 2026. The revised range represents an increase of 10.1% to 14.1% over the initial target and year-on-year growth of 94.2% to 101.4% compared with 2025 revenue of €6.950 million. The company said the new guidance reflects first-half performance, business activity seen since the start of the second half and the expected contribution from the TEXCELL activities and assets since their acquisition. For the first half of 2026, ABL Texcell Diagnostics reported revenue of €5.415 million, up 90.0%, EBITDA of €1.315 million and an EBITDA margin of 24.3%, with EBIT of €1.115 million and net profit of €1.280 million. The Évry Commercial Court selected the company on 21 July 2026 to acquire TEXCELL's activities and assets, a deal that includes continued operations at the Genopole site in Évry-Courcouronnes and the integration of 29 employees, and the guidance counts only the acquired activities from their effective transfer date. The company also cited its first publicly announced partnership with ABIONYX Pharma for viral safety and viral clearance studies on CER-001, and shareholders approved the new corporate name ABL Texcell Diagnostics at an Extraordinary General Meeting on 17 September 2026.

The global biomarkers market is projected to grow from USD 67.95 billion in 2026 to USD 112.10 billion by 2031, a 10.5% compound annual growth rate, according to a new ResearchAndMarkets.com report. Within the market's efficacy biomarkers segment, predictive biomarkers held the largest share in 2024 and continued to lead into 2025, driven by their role in matching patients to specific therapies across oncology, autoimmune and infectious diseases. In June 2026 the FDA approved Roche's first companion diagnostic for assessing PTEN protein status in prostate cancer, the VENTANA PTEN assay. Immunoassays retained the largest share of the technology segment in 2025, with Roche's Elecsys Anti-p53 and Abbott's ARCHITECT and Alinity systems cited among the leading platforms. Asia Pacific is forecast to record the fastest regional growth from 2026 to 2031, supported by healthcare infrastructure expansion in China, India and Japan. The 732-page report profiles Roche, Merck KGaA, Abbott, Thermo Fisher Scientific, QIAGEN, Illumina and other key players.

Abbott Laboratories has launched SimpleScreen CRC in the United States, an FDA-approved blood-based colorectal cancer screening test aimed at average-risk adults who decline traditional screening methods. The rollout comes alongside new clinical use of Abbott's Volt PFA system for atrial fibrillation and the continuation of its long-running dividend stream. Abbott's shares have fallen about 10.2% over the past month while gaining 9.5% over 90 days, leaving the 1 year total shareholder return down 22.9%, the 3 year total shareholder return up 12.2% and the 5 year total shareholder return slightly negative at 4.0%, with the stock at US$100.95. The most followed analyst narrative puts Abbott's fair value at $120.26, implying the shares are 16% undervalued, while the SWS DCF model points to a future cash flow value of $80.68. That narrative assumes scaling of the cancer diagnostics portfolio following the Exact Sciences acquisition, with 13% comparable growth in early 2026, care gap programs ramping in the second half and an expected contribution of about US$3b of 2026 sales, though ongoing Nutrition legal settlements and higher Libre expansion spending remain pressure points.

Abbott announced the U.S. commercial launch of SimpleScreen CRC, an FDA-approved blood-based colorectal cancer screening test for adults age 45 and older at average risk for the disease. Developed and manufactured by Freenome and exclusively commercialized by Abbott, SimpleScreen CRC joins the Cologuard Plus test in Abbott's colorectal cancer screening portfolio, giving healthcare providers both stool- and blood-based options. The test was evaluated in PREEMPT CRC, the largest prospective clinical validation study for a blood-based colorectal cancer screening test, which enrolled more than 48,000 asymptomatic, average-risk adults ages 45 to 85. In a prespecified analysis adjusted to match the U.S. Census, SimpleScreen CRC demonstrated 81.1% overall sensitivity for colorectal cancer, including 63.5% sensitivity for Stage I CRC, 13.7% sensitivity for advanced precancerous lesions, and 90.4% specificity for advanced colorectal neoplasia. SimpleScreen CRC is covered by Medicare, with no out-of-pocket costs for eligible patients with Medicare Part B, while Medicare Advantage patients may have out-of-pocket costs.

TIB MOLBIOL, a subsidiary of Roche Diagnostics, has launched the LightMix Newborn TREC/SMN1/HBB kit, an in vitro diagnostic test for newborn screening in countries accepting the CE mark. The test simultaneously screens for Spinal Muscular Atrophy, Severe Combined Immunodeficiency Disease, and Sickle Cell Disease, and provides private and academic hospital laboratories with a ready-to-use solution that integrates into existing workflows on established LightCycler systems. Marcus Droege, CEO of TIB MOLBIOL, said catching these diseases before symptoms appear is the difference between a child thriving or facing severe, lifelong disability, and that expanding the company's compliant newborn screening tools across Europe helps laboratories transition to high-precision solutions. Early diagnosis of SMA allows clinicians to immediately initiate targeted therapies that may halt severe nerve damage and prevent permanent disability, while early detection of SCD enables preventive penicillin and specialised immunisations that can drastically lower infant mortality, and early detection of SCID allows for lifesaving treatments such as bone marrow transplants before dangerous infections occur.

Labcorp Holdings is expanding in high-growth specialty testing markets while broadening its consumer testing business, with acquisitions, health-system relationships and new contracts boosting its reach. In the second quarter of 2026, the company completed acquisitions of select Parkview Health outreach laboratory services and Tribal Diagnostics, invested $225.7 million in acquisitions, and secured another Department of Defense contract to provide testing across military hospitals worldwide; net acquisitions added 1.2% to enterprise revenue growth and 1.9% to Diagnostics growth during the quarter. Enterprise adjusted operating margin expanded 70 basis points year over year to 15.8% in the second quarter of 2026, with Diagnostics margin up 50 basis points to 18% and BLS margin up 130 basis points to 17%. Management estimated that Affordable Care Act-related changes reduced second-quarter 2026 diagnostic volume by 20-30 basis points and continues to assume a 30-basis-point full-year impact, though the affected payer group represents less than 4-5% of diagnostic volume. Over the past 30 days, the Zacks Consensus Estimate for Labcorp's 2026 earnings per share has edged up 0.2% to $18.32, while the 2026 revenue consensus stands at $14.75 billion, implying 5.7% growth over 2025.

Qiagen has received U.S. FDA clearance for its QIAstat-Dx gram-negative bloodstream infection panel, giving American laboratories full access to the company's rapid sepsis testing portfolio in a single automated system. The clearance lands after a period of mixed trading for the NYSE-listed QGEN, with the share price up 15.1% over the past 90 days but still down 5.4% year to date, while the 1-year total shareholder return of 3.2% points to modest longer term gains. A widely followed narrative puts Qiagen's fair value at $46.27, only slightly above the last close at $45.01, a tight but meaningful gap for valuation debates. On a price-to-earnings basis, the stock trades at 22.7x earnings, above a fair ratio of 20.2x but below peer levels at 44.6x and the wider Life Sciences group at 38.3x. The company's story could break if QuantiFERON immigration volumes stay weak for years and if tight research budgets keep labs delaying higher margin instrument upgrades.

QIAGEN announced that U.S. labs now have access to its full QIAstat-Dx bloodstream infection portfolio after FDA clearance of a one-hour gram-negative bacteria and antibiotic resistance panel, which complements an existing gram-positive and fungal panel. The clearance broadens QIAGEN's coverage to 33 bloodstream pathogen targets and 28 resistance markers, reinforcing the clinical relevance of its automated QIAstat-Dx platform in guiding treatment decisions for life-threatening infections like sepsis. The company's narrative projects $2.5 billion revenue and $563.2 million earnings by 2029, requiring 6.0% yearly revenue growth and about a $153.9 million earnings increase from $409.3 million today. Some of the lowest analysts were already cautious, assuming only about 4.6% annual revenue growth to roughly US$2.4 billion and earnings of US$581 million, and they worry that if new panels like QIAstat-Dx's bloodstream tests fail to convert early traction into sustained adoption, Qiagen's growth story could look very different from the consensus view.

Biogen's growth portfolio generated $1.06 billion in second-quarter 2026 revenues, up 24% year over year and 25% sequentially, surpassing the company's legacy MS portfolio, which brought in $767 million. Even excluding newly acquired Syfovre and Empaveli, growth-product revenues reached $933 million, up 9% year over year and 10% quarter over quarter, still above the legacy MS portfolio. Within the growth portfolio, Skyclarys revenues rose 29% to $168 million, Zurzuvae increased 53% to $71 million, Spinraza grew 2% to $402 million, and Vumerity fell 7.4% to $196.5 million, while Syfovre and Empaveli contributed $97.4 million and $30.4 million respectively. Alzheimer's collaboration revenues from Eisai for Leqembi rose 16% to $63.7 million, and the companies expect blood-based diagnostics and the launch of Leqembi Iqlik to drive further growth from 2027 onward. Biogen expects the growth portfolio to maintain its lead in the second half of 2026, with Syfovre and Empaveli contributing more than in the second quarter since revenue recognition began only in mid-May.

Mission Bio announced that Merck & Co. and Incyte will each present new data generated using its Assay Services and Tapestri Platform at the 16th World Clinical Biomarkers & Companion Diagnostics Summit, alongside a third presentation from Mission Bio itself featuring new clinical data in acute myeloid leukemia. Merck scientist Sydney Hart will present functional genomics findings from a targeted DNA and RNA single-cell assay built with Mission Bio's Assay Services team to study how CRISPR-edited genetic variants affect immune cell function in autoimmune and inflammatory disease, work that links target validation to drug development decision-making. Incyte's Erin Crowgey will present new single-cell clinical data on INCA033989, a monoclonal antibody targeting mutant calreticulin-positive cells in essential thrombocythemia and myelofibrosis, generated with a custom Tapestri assay measuring 46 proteins and 37 genes in the same cell, showing depletion of mutant CALR-positive cells and repopulation by wild-type cells with relevant clinical improvements. Mission Bio Chief Medical Officer Zivjena Vucetic will present clinical study data showing single-cell multiomics achieved 93% sensitivity for measurable residual disease in AML compared to 43% for flow cytometry and 71% for other molecular methods, with additional evidence supporting more accurate stratification of relapse-free survival. The three presentations illustrate how single-cell multiomics connects genetic variation to cellular function, characterizes treatment response in individual cell populations, and identifies residual disease with greater resolution across drug development pipelines.

Leica Biosystems, a Danaher company, has completed its acquisition of privately held StatLab Medical Products, a leading provider of pre-analytical consumables and equipment, from Linden Capital Partners and Audax Private Equity. The transaction closed on September 28, 2026. The company said the deal unites StatLab's trusted portfolio and deep customer relationships with Leica Biosystems' global leadership in digital and computational pathology and AI-enabled diagnostics, expanding its end-to-end anatomic pathology ecosystem from specimen collection and preparation through advanced staining, digital imaging and AI-enabled diagnosis. Gustavo Perez-Fernandez, Group Executive of Danaher's Diagnostics Business and President of Leica Biosystems, said the combined businesses are better positioned to help laboratories achieve the consistency, standardization and quality needed to advance precision oncology at scale. Leica Biosystems said the expanded offering is designed to help pathology laboratories optimize histology workflows and reduce variation amid rising case volumes, increasing complexity and ongoing staffing pressures, and that both businesses remain focused on supporting customers with the same commitment to quality, service and partnership.

Snibe announced on September 28 that it has received one Medical Device Registration Certificate issued by the National Medical Products Administration. In the first half of 2026, Snibe achieved revenue of 2.42 billion yuan and net profit attributable to the parent of 868 million yuan.

Adaptive Biotechnologies is back in focus after the National Comprehensive Cancer Network updated its multiple myeloma guidelines to more fully embed minimal residual disease testing and explicitly reference the company's clonoSEQ assay. Investors reacted quickly to the guideline update, with Adaptive Biotechnologies' share price up 6.02% over the past day and posting a 12.65% 30-day share price return. The 1-year total shareholder return of 125.21% and 3-year total shareholder return above 4x suggest strong momentum that has only recently started to recover from a 5-year total shareholder return decline of 13%. The most followed narrative pegs Adaptive Biotechnologies' fair value at $26.36 against a last close of $29.57, implying the stock is 12% overvalued. The story could break if reimbursement shifts under the proposed 2027 CMS fee schedule, or if key partnerships underperform and dilute the company's MRD thesis.

A panel of US FDA advisors voted 6-4 that there is reasonable evidence GRAIL's multi-cancer early detection blood test Galleri is effective. Members of the Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee also voted 10-0 that the test is safe and 7-2 with one abstention that its benefits outweigh the risks, which include false positive or negative readings. Panel member Victor van Berkel of University of Louisville Physicians said that if more early-stage cancers can be found in the population that cannot currently be screened for, that will end up having benefit, though some members noted the test should be used in addition to current cancer screening methods rather than as a replacement. While Galleri is currently available in the US through cash payment, approval would mean coverage by Medicare and private insurance. A decision from the FDA is expected in the first part of 2027.

Maccura Biotechnology announced that the company recently received Medical Device Registration Certificates issued by the Sichuan Provincial Medical Products Administration, covering a total type I collagen amino-terminal extension peptide assay kit, a beta-collagen special sequence assay kit, and an osteocalcin assay kit. All are direct chemiluminescence reagents used to assist in the diagnosis of osteoporosis. To date, the company has obtained a cumulative total of 145 reagent product registration certificates on its direct chemiluminescence platform.

Yangpu Medical announced on September 24 that its wholly-owned subsidiary, Guangzhou Yangpu Medical Devices Co., Ltd., has completed the renewal of its EU Quality Management System certificate under the In Vitro Diagnostic Regulation, and obtained a newly issued EU Quality Management System certificate from the international certification body TÜV SÜD. The announcement said that passing this renewal means the sterile sample container products manufactured by Yangpu Medical Devices meet the requirements of EU Regulation IVDR 2017/746, giving them the necessary conditions to enter the EU market and having a positive impact on the company's overseas sales of related products. In the first half of 2026, Yangpu Medical achieved revenue of 215 million yuan and net profit attributable to the parent company of 30.81 million yuan.

Siemens Healthineers and Novo announced a new collaboration to address MASLD and MASH using non-invasive diagnostics. The partnership focuses on expanding disease awareness and clinical use of less invasive tools for assessing liver health and progression risk, with both groups aiming to support earlier identification of at-risk patients. Siemens Healthineers, a €41.5b medical equipment group, sells diagnostic and therapeutic technologies to hospitals and clinics worldwide, giving it a direct route to embed new non-invasive liver tools into everyday clinical workflows for metabolic disease care. The agreement plugs into Siemens Healthineers' push toward higher quality, recurring revenue through diagnostics, digital tools and AI driven decision support, and the link to Novo speaks to its role in chronic disease management. Investors can watch for concrete signs that MASLD and MASH testing is actually being used, such as new contracts tied to non invasive liver panels, updates on test volumes in metabolic disease programs with Novo, or commentary in upcoming results calls.

Polaris Capital Management's Global Equity Strategy highlighted Lantheus Holdings in its second-quarter 2026 investor letter, citing strong quarterly earnings, the FDA approval of PYLARIFY TruVu, and intensified M&A interest from a potential $7 billion takeover bid by PE-backed Curium Pharma. The Polaris Global Equity Composite returned 13.26% net of fees for the quarter, trailing the MSCI World Index's 13.90% return with gross dividends reinvested, but remained ahead year-to-date through June 30, 2026, gaining 19.95% versus 9.94% for the benchmark. Lantheus closed at $100.28 per share on September 22, 2026, down 0.58% over the past month but up 92.62% over the past 52 weeks, with a market capitalization of $6.55 billion and a 52-week range of $49.67 to $111.86. Forty hedge fund portfolios held Lantheus at the end of the second quarter, up from 31 in the previous quarter.

Asia Plus Securities stated that the Government Pharmaceutical Organization, together with Chulalongkorn University and Seqker Biosciences, is developing a personalised cancer vaccine that uses patients' genetic data to stimulate the immune system to attack cancer cells specifically. The vaccine is currently in phase 3-4 clinical research and has begun use in two foreign patients, with plans to extend into Medical Visa services and expand to state hospitals. The goal is to reduce treatment costs from 4-7 million baht to around 1 million baht. The research team views the private hospital sector positively over the medium to long term, because personalised cancer vaccines tend to complement Precision Medicine and Immunotherapy rather than replace existing treatments, creating opportunities to increase revenue per patient throughout the cancer treatment process, from genetic testing and laboratories to treatment and follow-up. It assesses that BH and BDMS are the main beneficiaries, maintains an overweight stance on the hospital sector relative to the market, and keeps buy recommendations on BH and BDMS with 2027 fair values of 225.00 baht and 25.00 baht respectively.

The Ministry of Industry and Information Technology and nine other ministries jointly released the 15th Five-Year Plan for the Development of the Pharmaceutical Industry, explicitly positioning biomedicine as a national emerging pillar industry and setting quantitative targets including revenue of pharmaceutical enterprises above designated size exceeding 3.5 trillion yuan by 2030 and average annual growth of the innovative drug industry above 20 percent. The National Medical Products Administration recently issued the world's first medical device standard for AI-based EEG brain-computer interface data, marking a new stage of standardized regulation for the integration of AI and medical hardware. At the industry level, the pace of Chinese innovative drugs going overseas has accelerated further this year, with total out-licensing transaction value exceeding 120 billion US dollars, up 36 percent year on year, of which upfront payments exceeded 10 billion US dollars. Huayuan Securities research notes point out that the policy environment for innovative drugs has improved on both the approval and payment sides, clinical CRO demand continues to recover, and the market is expected to keep expanding. Driven by this, as of 10:06 on September 23, 2026, the underlying index of Penghua STAR Market Pharmaceutical ETF, the SSE STAR Market Biomedical Index, rose 1.28 percent, with constituent stocks HOB Biotech up 20.00 percent, Medicilon up 7.62 percent, and Haoyuan Chemexpress up 7.24 percent; the underlying index of Penghua Vaccine ETF, the CNI Vaccine and Biotechnology Index, rose 1.13 percent.

Goldman Sachs initiated coverage of Tempus AI with a Neutral rating and a $75 price target on September 21, flagging renewal risk in the company's data business even as diagnostics growth stays visible. The call landed the same day Tempus announced an extension of its partnership with Recursion Pharmaceuticals through 2029, replacing potentially discretionary fees with $42 million of committed payments. Tempus generated $382.5 million of second-quarter revenue, up 22% year-over-year, with Diagnostics revenue up 20% to $289.3 million, oncology volumes up 31%, and MRD testing at 9,000 tests, up 38% from the prior quarter. The Data and Applications segment grew faster, with revenue up 28% in the quarter and Insights revenue up 36%, alongside roughly $200 million in new Data and Applications licenses signed during the quarter. Management estimates FDA approval of tumor-only xT CDx could add about $85 million of annual revenue beginning in 2027, while the company also received FDA clearance for a third cardiovascular AI product and was selected for an ARPA-H program worth up to $9.5 million. Short interest stood at 29.46 million shares, or 29.17% of the float, down from 33.23 million a month earlier, while ARK Investment Management raised its stake 5% to 10.02 million shares and Citadel expanded its position 318% to 2.51 million shares.

Agilent Technologies Inc. announced the launch of the Agilent 4150 TapeStationDx system, the Agilent 4200 TapeStationDx system and Agilent TapeStationDx software, extending its automated electrophoresis portfolio into regulated clinical laboratory environments. The new CE-IVD-labeled systems and software are designed to support standardized and traceable quality control of DNA and RNA samples used in clinical next-generation sequencing workflows, and Agilent said it is among the first providers to offer CE-IVD-labeled automated electrophoresis solutions for clinical NGS sample quality control in the launch regions. The 4150 TapeStationDx system supports lower-throughput laboratories with the flexibility to analyze 1 to 16 samples using tube strips, while the 4200 TapeStationDx system provides scalable throughput from 1 to 96 samples using either tube strips or 96-well plates at a constant cost per sample, with both systems delivering automated sample quality control in approximately 1 to 2 minutes per sample. The accompanying TapeStationDx software controls data acquisition and analysis and includes reporting and data export capabilities, with data integrity features such as audit trails and electronic signatures to help laboratories support compliance with regulations including 21 CFR Part 11 and EU Annex 11. The systems and software are available in the United States, Canada and select European markets including Austria, Belgium, Luxembourg, Switzerland, Germany, Denmark, Spain, Finland, France, the United Kingdom, Ireland, Italy, the Netherlands and Sweden, and Agilent will showcase the portfolio at the Italian Society of Human Genetics National Congress, the American Society of Human Genetics Annual Meeting and the Association for Molecular Pathology Annual Meeting.

Thai Life Insurance, or TLI, has announced a partnership with Bangkok Dusit Medical Services Public Company Limited, or BDMS, to provide special health benefits to customers of the "Thai Life Insurance LiveVerse" insurance plan, covering prevention and screening, treatment, and health rehabilitation. Mr. Chan Hao Chong, Senior Assistant Managing Director and Chief Proposition Officer of TLI, said that LiveVerse is a plan that allows lifetime life planning, or One Account for a Lifetime. The first plan launched is Thai Life Insurance LiveVerse Wealth Fit 99/99. The special benefits from BDMS are divided into three main categories. The first is core privileges, such as the Cancer Navigator service, specially priced surgical packages, and the Cancer Recovery Package. Next are optional health services, from which customers can choose one item, such as a hospital discount coupon worth 1,000 baht and a basic cancer screening program. The third category is special services for families when a Family Account is linked, which includes a program to assess the risk of 10 types of cancer using the Cancer Look Out genetic testing kit and SPOT-MAS technology, as well as a program to detect Alzheimer's disease risk. Customers can check their benefits and claim coupon codes through the Thai Life Insurance application, with claims available from today until May 31, 2570, and services accessible until June 30, 2570.

IDEXX Laboratories reaffirmed its long-term growth targets of more than 10% organic revenue growth and more than 15% earnings-per-share growth, with Chief Executive Officer Mike Erickson citing an exceptional second quarter and double-digit growth in reference laboratory and VetLab recurring revenue during the Morgan Stanley Global Healthcare Conference. The company's guidance incorporates an approximately 1.5% decline in clinical veterinary visits in the second half at the midpoint of its outlook, though Chief Financial Officer Andrew Emerson noted first-half results came in somewhat better than expected. IDEXX sees a $45 billion global diagnostics total addressable market and said bloodwork inclusion in wellness visits has risen about 50 basis points annually across the sector, while pets are living roughly 1.5 years longer than a decade ago, a 12% lifespan increase that has lifted diagnostic lifetime value by at least 16%. On the pipeline, the inVue Dx cytology platform is already within its targeted range of $3,500 to $5,500 in annual recurring revenue per instrument, with fine-needle aspirate testing in a controlled launch ahead of broader availability by year-end, and the Cancer Dx test is expanding from lymphoma into a multi-cancer panel covering lymphoma, mast cell tumors and hemangiosarcoma at a price of $15 when paired with a bloodwork panel. IDEXX has nearly 80,000 Catalyst instruments installed globally and expects to introduce proBNP testing on Catalyst in October, while maintaining a full-year comparable operating margin target above 32% and targeting average annual operating-margin expansion of 50 to 100 basis points over time.

Novo Nordisk will shorten its name to Novo and update its logo, with its trademark bull shifting to face right, as the Danish drugmaker battles Eli Lilly for dominance in the obesity-drug market. CEO Mike Doustdar is pushing to make Novo leaner and more competitive, and the company will detail its updated corporate strategy at a Capital Markets Day on September 21 in London. Separately, Eli Lilly said the U.S. FDA granted full approval for an all-oral regimen combining its estrogen receptor antagonist Inluriyo and kinase inhibitor Verzenio as a late-line option for adults with estrogen receptor-positive, HER2-negative breast cancer with an ESR1 mutation whose disease progressed after one or more prior endocrine therapies. GE HealthCare Technologies is in advanced talks to acquire Sofie Biosciences for about $1 billion, a deal that would expand its presence in radioactive diagnostic agents used with medical scans, according to the Financial Times. Summit Therapeutics said ivonescimab reduced the risk of death by 27% versus Merck's Keytruda in a late-stage lung cancer trial, with median overall survival of 30.8 months versus 22.6 months. Medtronic launched an exchange offer to split off at least 80.1% of MiniMed Group, allowing shareholders to exchange ordinary shares for MiniMed common stock at a 7% discount.

S&P Global agreed to acquire on-chain security assessments platform OpenZeppelin, one of a series of deals reported across sectors this week. Pearson announced the acquisition of ITS, a Baltimore-based assessment technology provider specializing in the management, delivery, and reporting of testing programs, with financial terms not disclosed. GE HealthCare Technologies is in advanced talks to acquire Sofie Biosciences for about $1 billion, a move that would expand its presence in radioactive diagnostic agents used with medical scans, according to the Financial Times. Brookfield agreed to acquire plumbing products manufacturer Reliance Worldwide for about $2.9B in an all-cash deal, valuing Reliance at $3.38 per share, equivalent to A$4.75 per share, a roughly 32% premium to its August 17 closing price. Mistras Group agreed to be acquired by investment firm H.I.G. Capital in an all-cash deal with an $866M enterprise value, including debt, while Aethlon Medical shares soared 346% premarket after it agreed to an all-stock merger with North Immunology, and Reuters reported that state-owned China Rare Earth Group is in talks to acquire Shenghe Resources.

Tempus AI is building a research platform based on 100,000 whole genomes linked to long term clinical records, a project that follows its $1.5 billion acquisition of Personalis. The Personalis deal strengthens Tempus' position in molecular residual disease testing, expanding the company from diagnosing and selecting cancer treatments into monitoring patients for cancer recurrence. The new whole genome project arrives after a sharp run in the shares, with a 90 day share price return of 62.68% and a 7 day gain of 31.91%, though the 1 year total shareholder return shows an 11.79% decline. Tempus AI closed at $77.84 against a narrative fair value estimate of $75.68, a level at which 26 investors see the stock as 3% overvalued. The company still carries ongoing losses and meaningful debt, so any setback integrating Personalis could quickly challenge the upbeat narrative.

Agilent Technologies launched the Agilent S540MD, a slide scanner that holds up to 540 glass slides at once, in the United States on September 4, following its January debut in select European markets. The FDA-cleared scanner is built for high-volume pathology labs preparing for AI-assisted workflows, can be refilled while running, fits standard racks, and uses automated scan modes and tissue detection; Majken Nielsen, who runs Agilent's Clinical Diagnostics Division, framed it as a way to tie digitization to customers' staining workflows. The launch lands alongside Agilent's August 26 report of $1.88 billion in revenue for the quarter ended July 31, up 8.1% from a year earlier, with non-GAAP earnings per share up 18%, and management raised full-year non-GAAP earnings guidance to $6.18 to $6.21 per share. The S540MD is a rebadged Hamamatsu NanoZoomer S540MD, and Agilent offered no pricing, unit targets, or revenue estimate for it. Tariff refunds added $0.06 to non-GAAP earnings per share and feed into the raised outlook, while the fourth-quarter guide assumes no further refunds and calls for core revenue growth of 5.2% to 6.2%, down from 7.3% in the third quarter.